PCBase Sweden
PCBase Sweden är en databas för klinisk epidemiologisk forskning om prostatacancer som skapats via en länkning mellan Nationella Prostatacancerregistret (NPCR) och andra nationella register. NPCR är ett nationellt populationsbaserat kvalitetsregister som sedan 1996 omfattar i princip alla män som diagnostiserats med prostatacancer i Sverige. Mellan 1996 och 2023 har ca 246 500 män registrerats i NPCR- med uppgifter om tumörkarakteristik och primärbehandling. Mer information finns https://statistik.incanet.se/npcr. Dessutom finns data på 5 kontroller per fall.
Med hjälp av personnummer har NPCR länkats med Cancerregistret, Dödsorsaksregistret, Läkemedelsregistret, Patientregistret, Flergenerationsregistret, Befolkningsregistret och SCB´s Longitudinella integrationsdatabas för försäkring och arbetsmarknadsstudier (LISA).
Data som är tillgängliga i PCBase innefattar bland annat tumörklassifikation, primärbehandling, dödsorsak, data om öppen och slutenvård, läkemedelsuttagsmönster, socioekonomiska faktorer, och familjär anhopning.
Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory, Int J Epidemiol, 2016 Feb;45(1):73-82.
I PCBase Xtend; Prostate Cancer data Base Sweden eXended treatment and endpoint data, ingår alla män över 30 år som bott i Sverige mellan 1998 och 2024. Data på PSA, prostatabiopsier, MR prostata samt rekvisitionsläkemedel har samlats in för mer än 5 miljoner män från alla offentliga och privata vårdgivare i Sverige. Inga svenska nationella register innehåller sådan information. PSA, MR prostata, och biopsier samlades in både före och efter prostatacancerdiagnos liksom data för män som inte diagnostiserats med prostatacancer. Utöver dessa nya data ingår också liksom tidigare data från NPCR, andra hälsodataregister och demografiska databaser i PCBase Xtend.
kohortprofilen https://doi.org/10.1093/ije/dyaf172
Syfte:
Att tillhandahålla en populationsbaserad studiebas för forskning om prostatacancer. Databasen möjliggör observationsstudier med fall-kontroll eller kohort design som kan användas för studier med viktiga kliniska implikationer.
Kontakt för data - Pär Stattin
par.stattin@uu.se
Citering och åtkomst
Citering och åtkomst
Tillgänglighetsnivå:
Skapare/primärforskare:
Forskningshuvudman:
Data innehåller personuppgifter:
Ja
Typ av personuppgifter:
Uppgifter om hälsa som går att återkoppla till individ genom flera registerhållare
Kodnyckel existerar:
Ja
Data innehåller känsliga personuppgifter:
Ja
Citering:
Datainsamling - Övrigt
Datainsamling - Övrigt
Insamlingsmetod:
Övrigt
Tidsperiod(er) för datainsamling:
1996-01-01 - 2020-12-31
Datainsamlare:
- Akademiska sjukhuset - Urologi
Datakälla:
- Register/handlingar/förteckningar: Medicinska/kliniska
- Register/handlingar/förteckningar
Geografisk täckning
Geografisk täckning
Geografisk plats:
Lägsta geografiska enhet:
Land
Administrativ information
Administrativ information
Ansvarig institution/enhet:
Urologi
Ämnesområde och nyckelord
Ämnesområde och nyckelord
Ämnesklassificering enligt CESSDA:
Standard för svensk indelning av forskningsämnen 2025:
Nyckelord:
Publikationer
Publikationer
Citering:
Stattin P, Loeb S. "To measure is to know. If you cannot measure it, you cannot improve it": statistical modeling cannot compensate for unmeasured bias. Eur Urol. 2014;65(4):701-3.
SwePub:
Citering:
Jochems SHJ, Stattin P, Stocks T. Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic monitoring in prostate cancer should involve a cotinine test in current smokers: smoking cessation remains a cornerstone in preventive health care overall and for men with prostate cancer. Eur Urol. 2022;82(4):e115.
Citering:
Franck Lissbrant I, Hjälm Eriksson M, Lambe M, Törnblom M, Stattin P. Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227-34.
SwePub:
Citering:
Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base - a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73-82.
DOI:
SwePub:
Citering:
Stattin P, Robinson D, Lambe M. Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate cancer registries: current status and future directions. Eur Urol 2015;68:e110. Eur Urol. 2015;68(5):e110.
SwePub:
Citering:
Arnsrud Godtman R, Persson E, Bergengren O, Carlsson S, Johansson E, Robinsson D, et al. Surgeon volume and patient-reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scand J Urol. 2022;56(5-6):343-50.
SwePub:
Citering:
George G, Garmo H, Adolfsson J, Elf K, Gedeborg R, Holmberg L, et al. Use of antiepileptic drugs and risk of prostate cancer: a nationwide case-control study in Prostate Cancer data Base Sweden. J Oncol. 2023;2023:9527920.
DOI:
SwePub:
Citering:
Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol. 2014;191(2):350-7.
SwePub:
Citering:
Bill-Axelson A, Garmo H, Nyberg U, Lambe M, Bratt O, Stattin P, et al. Psychiatric treatment in men with prostate cancer - results from a nation-wide, population-based cohort study from PCBaSe Sweden. Eur J Cancer. 2011;47(14):2195-201.
SwePub:
Citering:
Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer. 2020;20(1):551.
SwePub:
Citering:
Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43.
DOI:
SwePub:
Citering:
Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur Urol. 2018;74(6):710-9.
Citering:
Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105(17):1306-13.
DOI:
SwePub:
Citering:
Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116-22.
SwePub:
Citering:
Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180-8.
SwePub:
Citering:
Robinson D, Garmo H, Holmberg L, Stattin P. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Cancer Causes Control. 2015;26(9):1289-97. 10.1007/s10552-015-0622-4
SwePub:
Citering:
Stattin P, Carlsson S, Holmström B, Vickers A, Hugosson J, Lilja H, et al. Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 2014;106(3):dju007.
DOI:
SwePub:
Citering:
Shore R, Yu J, Ye W, Lagergren J, Rutegård M, Akre O, et al. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Sci Rep. 2021;11(1):13486.
SwePub:
Citering:
Svensson J, Lissbrant IF, Gauffin O, Hjälm-Eriksson M, Kilany S, Fagerlund K, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021;55(1):1-8.
SwePub:
Citering:
Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, et al. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scand J Urol. 2016;50(5):338-45.
Citering:
Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, et al. Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. Int J Cancer. 2016;138(9):2154-60.
DOI:
SwePub:
Citering:
Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101-11.
SwePub:
Citering:
Pettersson A, Alm D, Garmo H, Hjelm Eriksson M, Castellanos E, Åström L, et al. Comparative effectiveness of different radical radiotherapy treatment regimens for prostate cancer: a population-based cohort study. JNCI Cancer Spectr. 2020;4(2):pkaa006.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, et al. Use of Phosphodiesterase Type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313(24):2449-55.
SwePub:
Citering:
Plym A, Voss M, Stattin P, Lambe M. Reply from authors re: Matthew T. Gettman. Assessing work disability after radical prostatectomy. Eur Urol 2016;70:72-3: The challenge of assessing work disability. Eur Urol. 2016;70(1):73-4.
SwePub:
Citering:
Egevad L, Micoli C, Samaratunga H, Delahunt B, Garmo H, Stattin P, et al. Prognosis of Gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Eur Urol Oncol. 2024;7(2):213-21.
Citering:
Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631-8.
SwePub:
Citering:
Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, et al. Patient-reported side effects 1 year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study. Eur Urol Oncol. 2024;7(3):605-13.
SwePub:
Citering:
Crump C, Stattin P, Brooks JD, Stocks T, Sundquist J, Sieh W, et al. Early-life cardiorespiratory fitness and long-term risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2187-94.
SwePub:
Citering:
Loeb S, Lambe M, Stattin P. Re: Editorial comment on use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma: D. F. Penson J Urol 2015;194:1710-1711. J Urol. 2016;195(4 Pt 1):1172-3.
SwePub:
Citering:
Bonde TM, Garmo H, Stattin P, Nilsson P, Gunnlaugsson A, Swanberg D, et al. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Acta Oncol. 2023;62(12):1815-21.
SwePub:
Citering:
Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, et al. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncol. 2021;60(12):1589-96.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol. 2016;70(5):824-8.
SwePub:
Citering:
Bonde TM, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill-Axelson A, et al. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scand J Urol. 2022;56(3):169-75.
SwePub:
Citering:
O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243-51.
SwePub:
Citering:
Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study. Eur J Cancer. 2014;50(10):1789-98.
SwePub:
Citering:
Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48(1):75-84.
SwePub:
Citering:
Fallara G, Lissbrant IF, Styrke J, Montorsi F, Gedeborg R, Sandin F, et al. Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncol. 2021;60(1):56-60.
SwePub:
Citering:
Lundström KJ, Garmo H, Gedeborg R, Stattin P, Styrke J. Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scand J Urol. 2021;55(3):221-6.
SwePub:
Citering:
Hermann M, Vikman H, Stattin P, Katawazai A, Gustafsson O, Styrke J, et al. Androgen deprivation therapy and the risk for inguinal hernia: an observational nested case control study. Am J Mens Health. 2021;15(6):15579883211058606.
SwePub:
Citering:
Jan M, Bonn SE, Sjölander A, Wiklund F, Stattin P, Holmberg E, et al. The roles of stress and social support in prostate cancer mortality. Scand J Urol. 2016;50(1):47-55.
SwePub:
Citering:
Bonn SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):57-64.
SwePub:
Citering:
Balabanova Y, Farahmand B, Stattin P, Garmo H, Brobert G. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. BMC Urol. 2022;22(1):15.
SwePub:
Citering:
Fridriksson JÖ, Holmberg E, Adolfsson J, Lambe M, Bill-Axelson A, Carlsson S, et al. Rehospitalization after radical prostatectomy in a nationwide, population based study. J Urol. 2014;192(1):112-9.
SwePub:
Citering:
Jochems SHJ, Fritz J, Häggström C, Järvholm B, Stattin P, Stocks T. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. 2023;83(5):422-31.
SwePub:
Citering:
Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020;126(1):142-51.
DOI:
SwePub:
Citering:
Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, et al. Work disability after robot-assisted or open radical prostatectomy: a nationwide, population-based study. Eur Urol. 2016;70(1):64-71.
SwePub:
Citering:
Gedeborg R, Garmo H, Thellenberg-Karlsson C, Fallara G, Styrke J, Franck Lissbrant I, et al. Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta Oncol. 2022;61(3):328-32.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 2017;3(10):1393-8.
SwePub:
Citering:
Plym A, Folkvaljon Y, Garmo H, Holmberg L, Johansson E, Fransson P, et al. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer. J Sex Med. 2014;11(8):2100-8.
DOI:
SwePub:
Citering:
Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, et al. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Med Res Methodol. 2018;18(1):161.
SwePub:
Citering:
Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer. 2021;21(1):1259.
SwePub:
Citering:
Scilipoti P, Liedberg F, Garmo H, Wilberg Orrason A, Stattin P, Westerberg M. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study. Scand J Urol. 2024;59:98-103.
SwePub:
Citering:
Bratt O, Carlsson S, Holmberg E, Holmberg L, Johansson E, Josefsson A, et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol. 2013;47(5):347-55.
SwePub:
Citering:
Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342-9.
SwePub:
Citering:
Godtman RA, Persson E, Cazzaniga W, Sandin F, Carlsson S, Ahlgren G, et al. Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: nationwide, population-based study. PLoS One. 2021;16(6):e0253081.
SwePub:
Citering:
Fallara G, Sandin F, Styrke J, Carlsson S, Lissbrant IF, Ahlgren J, et al. Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scand J Urol. 2021;55(3):184-91.
SwePub:
Citering:
Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, et al. Androgen deprivation therapy for prostate cancer and risk of dementia. BJU Int. 2019;124(1):87-92.
DOI:
SwePub:
Citering:
Ventimiglia E, Bill-Axelson A, Bratt O, Montorsi F, Stattin P, Garmo H. Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden. JAMA Netw Open. 2022;5(9):e2231015.
SwePub:
Citering:
Robinson D, Abdulkareem R, Nasrollah D, Ljung A, Hintze P, Wallby S, et al. Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging. JAMA Netw Open. 2023;6(8):e2330233.
SwePub:
Citering:
Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, Lissbrant IF, et al. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Int J Cancer. 2024;155(4):637-45.
DOI:
SwePub:
Citering:
Stattin K, Sandin F, Bratt O, Lambe M. The risk of distant metastases and cancer specific survival in men with serum prostate specific antigen values above 100 ng/ml. J Urol. 2015;194(6):1594-600.
SwePub:
Citering:
Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, et al. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. J Natl Cancer Inst. 2023;115(4):456-67.
DOI:
SwePub:
Citering:
Loeb S, Stattin P. Further evidence against a causal association between erectile dysfunction drugs and melanoma. Eur Urol. 2016;70(5):816-7.
SwePub:
Citering:
O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118(3):391-8.
DOI:
SwePub:
Citering:
Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142(12):2478-84.
DOI:
SwePub:
Citering:
Balabanova Y, Farahmand B, Garmo H, Stattin P, Brobert G. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ Open. 2022;12(5):e055485.
SwePub:
Citering:
Jochems SHJ, Stattin P, Häggström C, Järvholm B, Orho-Melander M, Wood AM, et al. Height, body mass index and prostate cancer risk and mortality by way of detection and cancer risk category. Int J Cancer. 2020;147(12):3328-38.
DOI:
SwePub:
Citering:
Klein RJ, Vertosick E, Sjoberg D, Ulmert D, Rönn AC, Häggström C, et al. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precis Oncol. 2022;6(1):25.
SwePub:
Citering:
Ventimiglia E, Gedeborg R, Styrke J, Robinson D, Stattin P, Garmo H. Natural history of nonmetastatic prostate cancer managed with watchful waiting. JAMA Netw Open. 2024;7(6):e2414599.
SwePub:
Citering:
Crump C, Stattin P, Brooks JD, Sundquist J, Sieh W, Sundquist K. Mortality risks associated with depression in men with prostate cancer. Eur Urol Oncol. 2024;S2588-9311(24)00089-0.
Citering:
Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. Public online reporting from a nationwide population-based clinical prostate cancer register. BJU Int. 2018;122(1):8-10.
DOI:
SwePub:
Citering:
Van Hemelrijck M, Garmo H, Holmberg L, Stattin P, Adolfsson J. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol. 2012;61(4):690-700.
SwePub:
Citering:
Stattin P, Franck Lissbrant I. Diagnosspecifika översikter är viktiga verktyg för cancervården. Läkartidningen. 2018;115;EYFW.
SwePub:
Citering:
Jochems SHJ, Fritz J, Häggström C, Stattin P, Stocks T. Prediagnostic markers of insulin resistance and prostate cancer risk and death: a pooled study. Cancer Med. 2023;12(12):13732-44.
DOI:
SwePub:
Citering:
Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol. 2017;35(31):3566-74.
Citering:
Stattin P. Mortality in older men with low-risk prostate cancer and high comorbidity. J Clin Oncol. 2015;33(9):1086-7.
SwePub:
Citering:
Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013;49(7):1588-99.
SwePub:
Citering:
Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncol. 2016;55(12):1461-6.
SwePub:
Citering:
Markt SC, Grotta A, Nyren O, Adami HO, Mucci LA, Valdimarsdottir UA, et al. Insufficient sleep and risk of prostate cancer in a large Swedish cohort. Sleep. 2015;38(9):1405-10.
DOI:
SwePub:
Citering:
Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502.
DOI:
SwePub:
Citering:
Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010 Jul 7;102(13):950-8.
DOI:
SwePub:
Citering:
Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698-704.
DOI:
SwePub:
Citering:
Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, et al. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101-8.
SwePub:
Citering:
Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53-8.
SwePub:
Citering:
Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Med Inform Decis Mak. 2015;15:96.
SwePub:
Citering:
Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, et al. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019;30(2):195-206.
SwePub:
Citering:
Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63.
SwePub:
Citering:
Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol. 2013;63(2):354-63.
SwePub:
Citering:
Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, et al. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. BJU Int. 2017;119(1):50-6.
DOI:
SwePub:
Citering:
Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. Int J Cancer. 2012;130(2):478-87.
DOI:
SwePub:
Citering:
Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430-6.
SwePub:
Citering:
Stenman C, Abrahamsson E, Redsäter M, Gnanapragasam VJ, Bratt O. Rates of positive abdominal computed tomography and bone scan findings among men with Cambridge Prognostic Group 4 or 5 prostate cancer: a nationwide registry study. Eur Urol Open Sci. 2022;41:123-5.
SwePub:
Citering:
Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, et al. Estimation of relative and absolute risks in a competing-risks setting using a nested case-control study design: Example from the ProMort study. Am J Epidemiol. 2019;188(6):1165-73.
DOI:
SwePub:
Citering:
Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486-93.
DOI:
SwePub:
Citering:
Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, et al. Mini review on the use of clinical cancer registers for prostate cancer: The National Prostate Cancer Register (NPCR) of Sweden. Front Med (Lausanne). 2019;6:51.
SwePub:
Citering:
Westerberg M, Larsson R, Holmberg L, Stattin P, Garmo H. Simulation model of disease incidence driven by diagnostic activity. Stat Med. 2021;40(5):1172-88.
DOI:
SwePub:
Citering:
Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16(7):e0255239.
SwePub:
Citering:
Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TM, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505-15.
SwePub:
Citering:
Godtman RA, Månsson M, Bratt O, Robinsson D, Johansson E, Stattin P, et al. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study. Scand J Urol. 2019;53(6):378-84.
SwePub:
Citering:
Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study. PLoS One. 2020;15(1):e0228447.
SwePub:
Citering:
Björklund J, Stattin P, Rönmark E, Aly M, Akre O. The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study. BJU Int. 2022;129(3):318-24.
DOI:
SwePub:
Citering:
Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117(6b):E36-45.
DOI:
SwePub:
Citering:
Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study. Eur Urol. 2017;72(1):125-34.
SwePub:
Citering:
Bergengren O, Garmo H, Bratt O, Holmberg L, Johansson E, Bill-Axelson A. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study. BMJ Open. 2019;9(12):e033944.
SwePub:
Citering:
Lin E, Garmo H, Van Hemelrijck M, Zethelius B, Stattin P, Hagström E, et al. Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes. JAMA Netw Open. 2022;5(8):e2225600.
SwePub:
Citering:
Fridriksson JÖ, Folkvaljon Y, Lundström KJ, Robinson D, Carlsson S, Stattin P. Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. J Surg Oncol. 2017;116(4):500-6.
DOI:
SwePub:
Citering:
Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, et al. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nat Chem Biol. 2017;13(7):771-8.
SwePub:
Citering:
Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, et al. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology. 2017;49(7):715-20.
SwePub:
Citering:
Gedeborg R, Sandin F, Thellenberg-Karlsson C, Styrke J, Franck Lissbrant I, Garmo H, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58.
DOI:
SwePub:
Citering:
Wirén S, Drevin L, Akre O, Robinson D, Stattin P. Fathering of dizygotic twins and risk of prostate cancer: nationwide, population-based case-control study. PLoS One. 2014;9(10):e110506.
SwePub:
Citering:
Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One. 2021;16(10):e0255966.
SwePub:
Citering:
Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design considerations for observational studies of drugs for advanced cancer. Pharmacoepidemiol Drug Saf. 2023;32(7):812-5.
DOI:
SwePub:
Citering:
Lundberg F, Robinson D, Bratt O, Fallara G, Lambe M, Johansson ALV. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. Acta Oncol. 2024;63:95-104.
Citering:
Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol. 2020;59(1):106-11.
SwePub:
Citering:
Stattin P, Fleming S, Lin X, Lefresne F, Brookman-May SD, Mundle SD, et al. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. BJU Int. 2024;134(1):96-102.
DOI:
SwePub:
Citering:
Van Hemelrijck M, Garmo H, Michaëlsson K, Thorstenson A, Akre O, Stattin P, et al. Mortality following hip fracture in men with prostate cancer. PLoS One. 2013;8(9):e74492.
SwePub:
Citering:
Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, et al. Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. Eur Urol. 2019;75(4):676-83.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining intermediate risk prostate cancer suitable for active surveillance. J Urol. 2019;201(2):292-9.
SwePub:
Citering:
Fallara G, Lissbrant IF, Styrke J, Montorsi F, Garmo H, Stattin P. Observational study on time on treatment with abiraterone and enzalutamide. PLoS One. 2020;15(12):e0244462.
SwePub:
Citering:
Ahlberg MS, Garmo H, Holmberg L, Bill-Axelson A. Variations in the uptake of active surveillance for prostate cancer and its impact on outcomes. Eur Urol Open Sci. 2023;52:166-73.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69(6):1135-41.
SwePub:
Citering:
Crump C, Stattin P, Brooks JD, Sundquist J, Bill-Axelson A, Edwards AC, et al. Long-term risks of depression and suicide among men with prostate cancer: a national cohort study. Eur Urol. 2023;84(3):263-72.
SwePub:
Citering:
Jansson KF, Akre O, Garmo H, Bill-Axelson A, Adolfsson J, Stattin P, et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol. 2012;62(4):656-61.
SwePub:
Citering:
Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU Int. 2019;123(3):421-8.
DOI:
SwePub:
Citering:
Mehtälä J, Zong J, Vassilev Z, Brobert G, Gabarró MS, Stattin P, et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS One. 2020;15(2):e0227552.
SwePub:
Citering:
Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, et al. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncol. 2019;58(1):110-8.
SwePub:
Citering:
Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sieh W, et al. Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. JNCI Cancer Spectr. 2023;7(4).
SwePub:
Citering:
Cazzaniga W, Godtman RA, Carlsson S, Ahlgren G, Johansson E, Robinson D, et al. Population-based, nationwide registration of prostatectomies in Sweden. J Surg Oncol. 2019;120(4):803-12.
DOI:
SwePub:
Citering:
Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, et al. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists. BJU Int. 2018;121(2):260-7.
DOI:
SwePub:
Citering:
Stranne J, Axen E, Franck-Lissbrant I, Fransson P, Frånlund M, Hugosson J, et al. Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. World J Urol. 2020;38(6):1397-411.
SwePub:
Citering:
Egevad L, Micoli C, Delahunt B, Samaratunga H, Orrason AW, Garmo H, et al. Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Virchows Arch. 2024;484(6):995-1003.
Citering:
Loeb S, Schlomm T, Stattin P. Associations do not equal causation: clinical relevance of statistical associations of phosphodiesterase type 5 inhibitors with prostate cancer progression and melanoma. Eur Urol. 2015;68(5):754-5.
SwePub:
Citering:
Alverbratt C, Vikman H, Hjälm Eriksson M, Stattin P, Franck Lissbrant I. Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. Scand J Urol. 2022;56(2):95-101.
SwePub:
Citering:
Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int. 2015;115(2):248-55.
DOI:
SwePub:
Citering:
Damber JE. Words of wisdom. RE: Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. Eur Urol. 2015;68(6):1102.
SwePub:
Citering:
Parker J, Crawley D, Garmo H, Lindahl B, Styrke J, Adolfsson J, et al. Use of warfarin or direct oral anticoagulants and risk of prostate cancer in PCBaSe: a nationwide case-control study. Front Oncol. 2020;10:571838.
SwePub:
Citering:
Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, et al. Snus use, smoking and survival among prostate cancer patients. Int J Cancer. 2016;139(12):2753-9.
DOI:
SwePub:
Citering:
Gedeborg R, Garmo H, Robinson D, Stattin P. Prescription-based prediction of baseline mortality risk among older men. PLoS One. 2020;15(10):e0241439.
SwePub:
Citering:
Bergengren O, Westerberg M, Holmberg L, Stattin P, Bill-Axelson A, Garmo H. Variation in prostate-specific antigen testing rates and prostate cancer treatments and outcomes in a national 20-year cohort. JAMA Netw Open. 2021;4(5):e219444.
SwePub:
Citering:
Jochems SHJ, Häggström C, Stattin P, Järvholm B, Stocks T. Association of blood pressure with prostate cancer risk by disease severity and prostate cancer death: a pooled cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1483-91.
SwePub:
Citering:
Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307-18.
DOI:
SwePub:
Citering:
Wirén SM, Drevin LI, Carlsson SV, Akre O, Holmberg EC, Robinson DE, et al. Fatherhood status and risk of prostate cancer: nationwide, population-based case-control study. Int J Cancer. 2013;133(4):937-43.
DOI:
SwePub:
Citering:
Beckmann K, Garmo H, Nilsson P, Franck Lissbrant I, Widmark A, Stattin P. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016. Acta Oncol. 2020;59(5):549-57.
SwePub:
Citering:
Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol. 2015;68(2):207-13.
SwePub:
Citering:
Aly M, Leval A, Schain F, Liwing J, Lawson J, Vágó E, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54(2):115-21.
Citering:
Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020;204(4):714-9.
SwePub:
Citering:
Grotta A, Bottai M, Adami HO, Adams SA, Akre O, Blair SN, et al. Physical activity and body mass index as predictors of prostate cancer risk. World J Urol. 2015;33(10):1495-502.
SwePub:
Citering:
Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593-601.
SwePub:
Citering:
Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, et al. Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus. Int J Cancer. 2018;143(8):1868-75.
DOI:
SwePub:
Citering:
Stattin P. Editorial comment to 'Swedish National Guidelines on prostate cancer part I and II' by Bratt et al. How to survey adherence to guidelines by use of clinical cancer registers. Scand J Urol. 2022;56(4):285-6.
SwePub:
Citering:
Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, et al. Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. J Surg Oncol. 2018;117(2):321-7.
DOI:
SwePub:
Citering:
Sverrisson I, Folkvaljon F, Chabok A, Stattin P, Smedh K, Nikberg M. Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer. Eur J Surg Oncol. 2019;45(3):341-6.
SwePub:
Citering:
Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol. 2010;184(4):1322-7.
SwePub:
Citering:
Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52(2):143-50.
SwePub:
Citering:
Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, et al. Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol. 2018;73(4):502-11.
SwePub:
Citering:
George G, Garmo H, Rudman S, Holmberg L, Robinson D, Stattin P, et al. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in Prostate Cancer data Base Sweden. Scand J Urol. 2020;54(1):20-6.
SwePub:
Citering:
Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, et al. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol. 2016;114(6):664-70.
DOI:
SwePub:
Citering:
Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, et al. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open. 2018;8(3):e020787.
SwePub:
Citering:
Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190(5):1742-9.
SwePub:
Citering:
Gedeborg R, Lindhagen L, Loeb S, Styrke J, Garmo H, Stattin P. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2022;56(2):104-11.
SwePub:
Citering:
Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010;44(6):384-90.
SwePub:
Citering:
Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, et al. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. BJU Int. 2018;121(2):209-16.
DOI:
SwePub:
Citering:
Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672-81.
SwePub:
Citering:
Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellström K, Fransson P, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-67.
DOI:
SwePub:
Citering:
Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, et al. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scand J Urol. 2016;50(4):255-9.
SwePub:
Citering:
Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426-35.
SwePub:
Citering:
Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406.
DOI:
SwePub:
Citering:
Franck Lissbrant I, Styrke J, Törnblom M, Hjelm Eriksson M, Axén E, Stattin P. Prostatacancerregistret – för patienter, sjukvård och forskning. Läkartidningen. 2024;121:23196.
Citering:
Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2016;50(1):21-8.
SwePub:
Citering:
Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P. Primary cancers before and after prostate cancer diagnosis. Cancer. 2012;118(24):6207-16.
DOI:
SwePub:
Citering:
Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, et al. Immediate versus delayed prostatectomy: Nationwide population-based study. Scand J Urol. 2016;50(4):246-54.
SwePub:
Citering:
Ventimiglia E, Bill-Axelson A, Adolfsson J, Aly M, Eklund M, Westerberg M, et al. Modeling disease trajectories for castration-resistant prostate cancer using nationwide population-based data. Eur Urol Open Sci. 2022;44:46-51.
SwePub:
Citering:
Bratt O, Drevin L, Prütz KG, Carlsson S, Wennberg L, Stattin P. Prostate cancer in kidney transplant recipients - a nationwide register study. BJU Int. 2020;125(5):679-85.
DOI:
SwePub:
Citering:
FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, et al. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018;21(2):228-37.
SwePub:
Citering:
Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):88-96.
SwePub:
Citering:
Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst. 2016;108(10).
DOI:
SwePub:
Citering:
Orrason AW, Westerberg M, Albertsen P, Styrke J, Robinson D, Garmo H, et al. Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy. PLoS One. 2022;17(11):e0277784.
SwePub:
Citering:
Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, et al. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Br J Cancer. 2024;130(2):308-16.
SwePub:
Citering:
Plym A, Clements M, Voss M, Holmberg L, Stattin P, Lambe M. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open. 2020;10(3):e032914.
SwePub:
Citering:
Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604.
SwePub:
Citering:
Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. Eur Urol. 2017;72(6):920-8.
SwePub:
Citering:
Westerberg M. Estimation in discrete time coarsened multivariate longitudinal models. Stat Methods Med Res. 2023;32(4):806-19.
SwePub:
Citering:
Fridriksson JÖ, Gunseus K, Stattin P. Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden. Scand J Urol Nephrol. 2012;46(5):326-31.
SwePub:
Citering:
Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: a nationwide population based study. J Urol. 2017;197(1):61-6.
Citering:
Ahlberg M, Garmo H, Stattin P, Gedeborg R, Edlund C, Holmberg L, et al. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study. Scand J Urol. 2024;59:63-9.
SwePub:
Citering:
Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010 May;11(5):450-8.
SwePub:
Citering:
Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, et al. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer. 2019;19(1):612.
SwePub:
Citering:
Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117(3):507-14.
DOI:
SwePub:
Citering:
Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, et al. Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy. Eur Urol. 2017;72(3):345-51.
SwePub:
Citering:
Bonn SE, Wiklund F, Sjölander A, Szulkin R, Stattin P, Holmberg E, et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control. 2014;25(8):933-43.
SwePub:
Citering:
Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy. Scand J Urol. 2016;50(3):155-9.
SwePub:
Citering:
Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158-63.
SwePub:
Citering:
Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833-9.
SwePub:
Citering:
Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sundquist K, et al. Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study. J Natl Cancer Inst. 2024;116(5):745-52.
DOI:
Citering:
Westerberg M, Beckmann K, Gedeborg R, Irenaeus S, Holmberg L, Garmo H, et al. Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence. J Clin Epidemiol. 2023;155:22-30.
SwePub:
Citering:
Shore R, Zhang J, Ye W, Stattin P, Lindblad M. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study. Cancer Causes Control. 2023;34(11):949-61.
SwePub:
Citering:
Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018;16(1):31.
SwePub:
Citering:
Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607-15.
SwePub:
Citering:
Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, et al. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer. 2018;142(11):2254-62.
DOI:
SwePub:
Citering:
Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-56.
SwePub:
Citering:
Wirén S, Stattin P. Forskning på kvalitetsregister ger klinisk nytta. Resultat från Nationella prostatacancerregistret. [Research on quality registries provides clinical benefit. Results from the National Prostate Cancer Registry]. Läkartidningen. 2012;109(26-28):1294-7.
SwePub:
Citering:
Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU Int. 2015;116(2):213-9.
DOI:
SwePub:
Citering:
Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-9.
SwePub:
Citering:
Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, et al. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control. 2013;24(2):383-90.
SwePub:
Citering:
Orrason AW, Garmo H, Styrke J, Dickman PW, Stattin P. Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category: a nationwide, population-based study. Am J Epidemiol. 2021;190(10):2053-63.
DOI:
SwePub:
Citering:
Westerberg M, Garmo H, Robinson D, Stattin P, Gedeborg R. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504.
SwePub:
Citering:
Thomsen FF, Garmo H, Egevad L, Stattin P, Brasso K. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer. Scand J Urol. 2024;59:76-83.
SwePub:
Citering:
George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, et al. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta Oncol. 2021;60(4):459-65.
SwePub:
Citering:
Lycken M, Drevin L, Garmo H, Larsson A, Andrén O, Holmberg L, et al. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study. Scand J Urol. 2020;54(3):208-14.
SwePub:
Citering:
Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U, Steineck G, Stattin P. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol. 2010 Mar;57(3):390-5.
SwePub:
Citering:
Beckmann K, Garmo H, Lindahl B, Holmberg L, Stattin P, Adolfsson J, et al. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer Prostatic Dis. 2020;23(3):527-33.
SwePub:
Citering:
Stattin P, Westerberg M, Lissbrant IF, Eriksson MH, Kjellman A, Ullén A, et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107.e1-.e9.
SwePub:
Citering:
Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, et al. Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. BJU Int. 2016;118(2):302-6.
DOI:
SwePub:
Citering:
Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin P, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak. 2022;22(1):35.
SwePub:
Citering:
Lin E, Garmo H, Hagström E, Van Hemelrijck M, Adolfsson J, Stattin P, et al. Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden. Br J Cancer. 2023;128(5):814-24.
SwePub:
Citering:
Melvin JC, Garmo H, Daniel R, Shanmugalingam T, Stattin P, Häggström C, et al. An investigation into the relationship between statins and cancer using population-based data. BJU Int. 2015;116(5):681-3.
DOI:
SwePub:
Citering:
Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, et al. Prostate cancer radiation therapy and risk of thromboembolic events. Int J Radiat Oncol Biol Phys. 2017;97(5):1026-31.
SwePub:
Citering:
Grundmark B, Garmo H, Zethelius B, Stattin P, Lambe M, Holmberg L. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619-30.
SwePub:
Citering:
Robertson S, Adolfsson J, Stattin P, Sjövall A, Winnersjö R, Hanning M, et al. Waiting times for cancer patients in Sweden: a nationwide population-based study. Scand J Public Health. 2017;45(3):230-7.
SwePub:
Citering:
Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O. Concordance of non-low-risk disease among pairs of brothers with prostate cancer. J Clin Oncol. 2018;36(18):1847-52.
SwePub:
Citering:
Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52(4):277-84.
SwePub:
Citering:
Ventimiglia E, Van Hemelrijck M, Lindhagen L, Stattin P, Garmo H. How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Med Inform Decis Mak. 2019;19(1):103.
SwePub:
Citering:
Nilsson H, Stranne J, Stattin P, Nordin P. Incidence of groin hernia repair after radical prostatectomy: a population-based nationwide study. Ann Surg. 2014;259(6):1223-7.
SwePub:
Citering:
Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P. Opioid use after radical prostatectomy: nationwide, population based study in Sweden. J Urol. 2020;203(1):145-50.
SwePub:
Citering:
Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS One. 2018;13(4):e0195690.
SwePub:
Citering:
Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140(3):611-7.
DOI:
SwePub:
Citering:
Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6):405-10.
SwePub:
Citering:
Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67(2):233-8.
SwePub:
Citering:
Braide K, Kindblom J, Thellenberg Karlsson C, Stattin P, Hugosson J, Månsson M. Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study. BJU Int. 2022;130(6):799-808.
DOI:
SwePub:
Citering:
Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer. Eur Urol. 2017;72(4):534-41.
SwePub:
Citering:
Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of fractures and falls during and after 5-α reductase inhibitor use: a nationwide cohort study. PLoS One. 2015;10(10):e0140598.
SwePub:
Citering:
Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O. Risk of postoperative up staging or upgrading among men with low risk familial prostate cancer. J Urol. 2020;204(1):79-81.
SwePub:
Citering:
Thurtle D, Bratt O, Stattin P, Pharoah P, Gnanapragasam V. Comparative performance and external validation of the multivariable PREDICT prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Med. 2020;18(1):139.
SwePub:
Citering:
Beckmann K, Garmo H, Franck Lissbrant I, Stattin P. The value of real-world data in understanding prostate cancer risk and improving clinical care: examples from Swedish registries. Cancers (Basel). 2021;13(4).
